AveXis Inc (NASDAQ:AVXS) insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $118.07, for a total transaction of $1,771,050.00. Following the transaction, the insider now directly owns 1,792,147 shares in the company, valued at $211,598,796.29. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of AveXis Inc (NASDAQ AVXS) opened at $115.14 on Wednesday. The firm has a market cap of $3,680.00 and a PE ratio of -20.63. AveXis Inc has a fifty-two week low of $53.94 and a fifty-two week high of $128.00.

AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same quarter last year, the firm earned ($0.87) EPS. analysts predict that AveXis Inc will post -6.23 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of AveXis by 57.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock valued at $137,000 after acquiring an additional 453 shares in the last quarter. Amalgamated Bank lifted its stake in shares of AveXis by 19.6% in the third quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock valued at $308,000 after purchasing an additional 523 shares during the period. Parametric Portfolio Associates LLC lifted its stake in shares of AveXis by 2.9% in the second quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock valued at $1,721,000 after purchasing an additional 598 shares during the period. Jennison Associates LLC lifted its stake in shares of AveXis by 0.5% in the fourth quarter. Jennison Associates LLC now owns 185,094 shares of the company’s stock valued at $20,484,000 after purchasing an additional 883 shares during the period. Finally, Strs Ohio acquired a new stake in shares of AveXis in the third quarter valued at about $116,000. 81.42% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have issued reports on the stock. William Blair reissued a “buy” rating on shares of AveXis in a research report on Tuesday, January 30th. BMO Capital Markets reissued a “buy” rating and set a $150.00 price objective on shares of AveXis in a research report on Thursday, January 18th. Credit Suisse Group assumed coverage on shares of AveXis in a research report on Wednesday, January 17th. They set an “outperform” rating and a $134.00 price objective on the stock. Royal Bank of Canada reissued a “hold” rating and set a $92.00 price objective on shares of AveXis in a research report on Tuesday, January 9th. Finally, Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the stock. AveXis currently has a consensus rating of “Buy” and a consensus price target of $113.89.

WARNING: “AveXis Inc (AVXS) Insider Brian K. Kaspar Sells 15,000 Shares” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/02/07/avexis-inc-avxs-insider-brian-k-kaspar-sells-15000-shares-2.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.